Get the Stockscreener App
1.35
9.76%
0.12
Citius Pharmaceuticals Inc stock is traded at $1.35, with a volume of 2.12M.
It is up +9.76% in the last 24 hours and down -7.53% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$1.23
Open:
$1.3
24h Volume:
2.12M
Relative Volume:
0.86
Market Cap:
$22.97M
Revenue:
-
Net Income/Loss:
$-39.14M
P/E Ratio:
-0.2261
EPS:
-5.97
Net Cash Flow:
$-28.20M
1W Performance:
+1.50%
1M Performance:
-7.53%
6M Performance:
-25.00%
1Y Performance:
-90.58%
1-Day Range:
$1.29
$1.43
1-Week Range:
$1.18
$1.45
52-Week Range:
$0.65
$17.00
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.35 | 23.48M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Citius Oncology Announces Closing of $9.0 Million Public Offering - ADVFN Brasil
Citius Pharma Reports Q2 2025 Financial Results - TipRanks
Using flow based indicators on Citius Pharmaceuticals Inc.July 2025 Technicals & Fast Moving Stock Watchlists - Newser
Predicting Citius Pharmaceuticals Inc. trend using moving averagesQuarterly Performance Summary & Consistent Return Investment Signals - Newser
Chart overlay techniques for tracking Citius Pharmaceuticals Inc.Market Activity Summary & Daily Momentum Trading Reports - Newser
Tick level data insight on Citius Pharmaceuticals Inc. volatilityGap Up & Community Consensus Trade Alerts - Newser
What technical models suggest about Citius Pharmaceuticals Inc.’s comebackEarnings Miss & AI Driven Stock Price Forecasts - Newser
What the charts say about Citius Pharmaceuticals Inc. todayJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - Newser
Will Citius Pharmaceuticals Inc. stock go up in YEARWeekly Investment Recap & Daily Chart Pattern Signals - mustnews.co.kr
Intraday pattern recognizer results for Citius Pharmaceuticals Inc.Quarterly Growth Report & Fast Entry Momentum Trade Alerts - Newser
AI Indicators Detect Buy Opportunity in Citius Pharmaceuticals Inc.July 2025 Trade Ideas & Consistent Profit Trading Strategies - beatles.ru
Price momentum metrics for Citius Pharmaceuticals Inc. explainedJuly 2025 Rallies & Verified Momentum Stock Ideas - Newser
Building trade automation scripts for Citius Pharmaceuticals Inc.Quarterly Profit Summary & Smart Money Movement Alerts - Newser
Why Citius Pharmaceuticals Inc. is moving todayIPO Watch & Low Drawdown Investment Strategies - Newser
Using R and stats models for Citius Pharmaceuticals Inc. forecastingSwing Trade & Weekly High Conviction Ideas - Newser
Ichimoku Cloud Indicates Uncertainty Around Citius Pharmaceuticals Inc.Trade Risk Report & Smart Allocation Stock Reports - 선데이타임즈
What is Citius Pharmaceuticals Inc. s debt to equity ratioEarnings Performance Report & Short-Term Trading Alerts - 선데이타임즈
Tools to assess Citius Pharmaceuticals Inc.’s risk profileMarket Trend Summary & Free Weekly Watchlist of Top Performers - Newser
Published on: 2025-08-15 17:50:31 - Newser
Citius Pharmaceuticals Q3 Earnings: Net Loss Narrows, Revenue Falls Short of Expectations. - AInvest
Citius Pharmaceuticals regains Nasdaq compliance with minimum bid price requirement. - AInvest
Citius Pharmaceuticals Inc. Volume Confirms Breakout — Analysts BullishFed Meeting & Consistent Profit Trade Alerts - beatles.ru
Citius Pharmaceuticals Inc. Uptrend in Early Stages Indicators Say YesPortfolio Value Report & Consistent Income Trade Ideas - thegnnews.com
Citius Pharmaceuticals (NASDAQ:CTXR) Receives “Buy” Rating from D. Boral Capital - Defense World
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Posts Wider Loss in Fiscal Q3 - The Globe and Mail
Citius: D. Boral Capital raises PT to $6, maintains Buy rating. - AInvest
Citius Pharmaceuticals shares fall 3.85% intraday after reporting fiscal third quarter results and raising $12.5 million in financings. - AInvest
Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
Citius Pharmaceuticals (NASDAQ:CTXR) Trading Up 4% – Time to Buy? - Defense World
Citius Oncology Beats Q3 EPS Estimates with $0 Revenue - AInvest
Citius Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year - TipRanks
LYMPHIR Launch Readiness vs. Cash Shortfall: Citius Oncology Raises $9M - Stock Titan
Citius Oncology Secures $21.5M Funding to Launch New Lymphoma Treatment LYMPHIR - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update - Ariva
Why Citius Pharmaceuticals Inc. stock attracts strong analyst attention2x Return in 30 Days Picks - 한국정경신문
Citius Oncology Announces Pricing of $9.0 Million Public Offering - ADVFN Brasil
Is Citius Pharmaceuticals Inc. stock a growth or value playTechnical Screener for High Growth Stocks - Newser
Sector ETF performance correlation with Citius Pharmaceuticals Inc.Risk Shielded Trade Watch with Analysis - Newser
Citius Oncology IncAnticipates Commercial Launch of Lymphir in 2025 - 富途牛牛
Citius Pharmaceuticals (CTXR) Expected to Announce Quarterly Earnings on Monday - Defense World
Citius CTXR 2025Q3 Earnings Preview Upside Ahead on Potential New Product Launch - AInvest
Published on: 2025-08-04 16:39:39 - beatles.ru
Published on: 2025-08-04 09:23:45 - beatles.ru
What is the dividend policy of Citius Pharmaceuticals Inc. stockMaximize your gains with expert trading tips - Jammu Links News
When is Citius Pharmaceuticals Inc. stock expected to show significant growthSpectacular growth rates - Jammu Links News
What are Citius Pharmaceuticals Inc. company’s key revenue driversUnstoppable trading performance - Jammu Links News
What institutional investors are buying Citius Pharmaceuticals Inc. stockAchieve breakthrough investment performance - Jammu Links News
Is Citius Pharmaceuticals Inc. a good long term investmentExceptional ROI - Jammu Links News
Why is Citius Pharmaceuticals Inc. stock attracting strong analyst attentionExceptional trading performance - Jammu Links News
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):